Teva, CRT Build On Tie That Produced aPKC Protein Inhibitor Candidate
This article was originally published in The Pink Sheet Daily
Executive Summary
By jointly finding a first-in-class atypical Protein Kinase C inhibitor preclinical candidate, Israel’s Teva and Britain’s Cancer Research Technology have successfully capped a four-year collaboration and are now branching out into the area of DNA damage response.
You may also be interested in...
Deal Watch: Oncology A Recurring Theme In Recent Spate Of Transactions
TetraLogic uses cash from its recent IPO to bring form to its oncology pipeline via the acquisition of Shape Pharmaceuticals. Also, GlaxoSmithKline becomes the latest big pharma to partner with MD Anderson Cancer Center’s Moon Shots program and Mersana will collaborate with Takeda on antibody-drug conjugates for cancer.
Cancer Research UK’s CRT: A Bridge Between Big Pharma And Academia
Britain’s Cancer Research Technology says the dire financing situation facing European biotechs has forced it to become a bridge builder between research-based Big Pharma and academia, an intermediary role that it expects to expand on as the search for new oncology drugs intensifies.
With Cephalon Deal, Teva Sees Opportunities For Niche Branded Drugs and Drug/Device Combinations
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: